Glenmark's consolidated revenue rises 7.96% to Rs. 27,674.89 Mn

▴ Glenmark's consolidated revenue rises 7.96% to Rs. 27,674.89 Mn
India Business grew by 14.52 % to Rs. 7,647.53 Mn.

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the fourth quarter and year ended March 31, 2020.

For the Fourth Quarter of FY 2019-20, Glenmark's consolidated revenue was at Rs. 27,674.89 Mn. as against Rs. 25,634.74 Mn. recording an increase of 7.96 %.

Consolidated Net Profit was at Rs. 2203.08 Mn. for the quarter ended March 31, 2019, as compared to Rs. 1,616.62 Mn. in the previous corresponding quarter, registering an increase of 36.28%.

Consolidated EBITDA grew by 27.89% to Rs. 4656.87 Mn. in the quarter ended March 31, 2020, as against Rs. 3,641.31 Mn. in the previous corresponding quarter.

For the year ended March 31, 2020, Glenmark's consolidated revenue was at Rs. 106,409.69 mn as against Rs. 98,654.69 Mn., recording an increase of 7.86% over the previous corresponding period. Consolidated Net Profit was at Rs. 7759.70 Mn. for the year ended March 31, 2020, as against Rs. 9,249.93 Mn. in the previous year. Consolidated EBITDA for the fiscal year ended March 31, 2020, stood at Rs. 16980.82 Mn. as against Rs. 15,857.99 Mn. in the previous corresponding period.

"Our growth momentum sustained in the Fourth Quarter despite the COVID-19 pandemic and challenging generic business environment across markets globally. Our India, Europe and Latin America regions performed well during the Quarter," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd. He further added, "Our sustained performance has been due to the continuous efforts of all our employees around the world. Our manufacturing facilities have operated continuously and facilitated the uninterrupted supply of medicines to operating markets."

Details

1. GLENMARK PHARMACEUTICALS LTD. (GPL)

India

Sales from the formulation business in India for the Fourth Quarter of FY 2019-20 was at Rs. 7,647.53 mn as against Rs. 6677.94 Mn in the previous corresponding quarter, recording growth of 14.52 %.

Glenmark Consumer Care Business

Glenmark Consumer Care business continued to maintain a strong growth momentum of 31 % in the quarter of this financial year and the business setting a new milestone of sales of INR 203.8 crore in this financial year.

USA

Glenmark Pharmaceuticals Inc., USA registered revenue from the sale of finished dosage formulations of Rs. 7,619.02 Mn for the quarter ended March 31, 2020, as against revenue of Rs. 7696 Mn for the previous corresponding quarter, recording a de-growth of (1 %)

Africa, Asia and CIS Region (ROW)

For the Fourth Quarter of FY 2019-20, revenue from Africa, Asia, and the CIS region was Rs. 3365.47 Mn as against Rs. 3852.85 Mn for the previous corresponding quarter, recording de-growth of (12.65 %)

Europe

Glenmark Europe's operations revenue for the Fourth Quarter of FY 2019-20 was at Rs. 4115.68 mn as against Rs. 3184.07 Mn recording a growth of 29.26 %.

Latin America

Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 1768.73 Mn for the Fourth Quarter of FY 2019-20, as against Rs. 1204.07 Mn., recording an increase of 46.9 %.

API Business

For the Fourth Quarter of FY 2019-20, external sales for Glenmark Life Sciences was at Rs. 2613.79 mn as against Rs. 2487.77 Mn., recording growth of 5.07 % over the corresponding period last year.

For the entire year, external sales of Glenmark Life Sciences recorded revenue of INR. 10239.17 Mn as against Rs. 9493.11 Mn. in the previous financial year, recording growth of 7.86 % over the corresponding period last year.

2. ICHNOS Sciences

For updates on the organization and the pipeline, please log on to www.ichnossciences.com. The pipeline update for the fourth quarter is published

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with a presence across Generics, Specialty, and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology, and oncology. It is ranked among the top 80 Pharma & Biotech companies in the world in terms of revenue (SCRIP 100 Rankings published in the year 2019).

Tags : #Glenmark #Q4FY2019-20Results #EBITDA #Pharmaceuticals #financial #Sales

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024